Bioxyne Ltd (BXN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Bioxyne Ltd (BXN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12411
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bioxyne Ltd (Bioxyne), is a biotechnology company that develops, manufactures, markets and commercializes healthcare products in the areas of immune health and immunotherapeutics. It manufactures consumer food supplements such as, ProTract and Progastrim, which are based on a proprietary probiotic strain PCC (lactobacillus fermentum). It also develops a range of existing functional food and beauty products containing ingredients sourced from New Zealand. The company caters to consumer dietary supplements and functional foods markets. Its products are used as dietary supplement and foodstuffs and beverages. The company has manufacturing and distribution agreements with Chr. Hansen and Nu-Skin Enterprises. The company distributes its products across North America and Europe. Bioxyne is headquartered in Sydney, New South Wales, Australia.

Bioxyne Ltd (BXN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bioxyne Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Bioxyne Enters into Agreement with Datapharm Australia 10
Equity Offering 11
Bioxyne Raises USD1.9 Million in Underwritten Non-Renounceable Right Issue 11
Bioxyne to Raise Funds through Private Placement of Shares 12
Bioxyne Completes Private Placement Of Shares For US$0.5 Million 13
Debt Offering 14
Bioxyne Announces Private Placement Of Notes For US$0.5 Million 14
Acquisition 15
Mariposa Health Completes Acquisition Of Hunter Immunology From Bioxyne For US$1.4 Million 15
Bioxyne Ltd – Key Competitors 16
Bioxyne Ltd – Key Employees 17
Bioxyne Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Financial Announcements 19
Feb 27, 2017: Bioxyne: Interim Financial Report For the Half Year ended 31 December 2016 19
Corporate Communications 21
May 01, 2018: Bioxyne: Non-Executive Director Appointment – Peter Charles Hughes-Hallett 21
Feb 15, 2018: Bioxyne: Resignation of Director 22
Product News 23
Dec 11, 2017: Positive Bioxyne Gut Health Clinical Trial Results 23
Other Significant Developments 24
Oct 29, 2018: Bioxyne: Quarterly report for the period ended 30 September 2018 24
Jul 27, 2018: Bioxyne: Quarterly report for the period ended 30 June 2018 25
Apr 27, 2018: Bioxyne: Quarterly Report for the Period ended 31 March 2018 26
Jul 31, 2017: Bioxyne: Quarterly Report for the Period Ended 30 June 2017 27
Apr 27, 2017: Bioxyne: Quarterly Report for the Period Ended 31 March 2017 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Bioxyne Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bioxyne Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bioxyne Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bioxyne Enters into Agreement with Datapharm Australia 10
Bioxyne Raises USD1.9 Million in Underwritten Non-Renounceable Right Issue 11
Bioxyne to Raise Funds through Private Placement of Shares 12
Bioxyne Completes Private Placement Of Shares For US$0.5 Million 13
Bioxyne Announces Private Placement Of Notes For US$0.5 Million 14
Mariposa Health Completes Acquisition Of Hunter Immunology From Bioxyne For US$1.4 Million 15
Bioxyne Ltd, Key Competitors 16
Bioxyne Ltd, Key Employees 17
Bioxyne Ltd, Subsidiaries 18

List of Figures
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Bioxyne Ltd (BXN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Taewoong Medical Co Ltd:企業の製品パイプライン分析2018
    Summary Taewoong Medical Co Ltd (Taewoong Medical) is a medical device company that develops and manufactures stents and other medical devices. The company offers products such as self-expandable metal stent, endoscopic RFA, endoscopic accessory, ureteral stent, airway stent, colonic stent, surgical …
  • Rhizen Pharmaceuticals SA-製薬・医療分野:企業M&A・提携分析
    Summary Rhizen Pharmaceuticals SA (Rhizen Pharma), a subsidiary of Alembic Pharmaceuticals Ltd is a biopharmaceutical company that discovers and develops small molecule drugs. The company’s research products includes c-Met inhibitors, selective P13K inhibitors, CRAC channel inhibitors and GPR 119 ag …
  • KBR Inc (KBR):石油・ガス:M&Aディール及び事業提携情報
    Summary KBR, Inc. (KBR) is a global provider of engineering, construction, and professional services and technologies. The company offers specialized engineering and design, technology licensing, program management, construction management, specialized consulting, operations, maintenance and other s …
  • Beaver Aerospace & Defense, Inc.:企業の戦略・SWOT・財務分析
    Beaver Aerospace & Defense, Inc. - Strategy, SWOT and Corporate Finance Report Summary Beaver Aerospace & Defense, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Jiangxi Copper Co Ltd:企業の戦略・SWOT・財務情報
    Jiangxi Copper Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Jiangxi Copper Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Ascential plc (formerly Top Right Group Limited):企業のM&A・事業提携・投資動向
    Ascential plc (formerly Top Right Group Limited) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ascential plc (formerly Top Right Group Limited) Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business descri …
  • Safe Orthopaedics SA (SAFOR):企業の財務・戦略的SWOT分析
    Summary Safe Orthopaedics SA (Safe Orthopaedics) is medical device company that manufactures and markets devices for spinal surgery. The company’s products comprise implants and surgical instruments. It also offers modular cervical cages, percutaneous auto-correction screws, modular anchorage screws …
  • CMS Energy Corporation:発電所・企業SWOT分析
    CMS Energy Corporation - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employ …
  • Larix AS-製薬・医療分野:企業M&A・提携分析
    Summary Larix A/S (Larix) is a contract research organization that offers services related to clinical trials assistance. The company provides services such as statistics, data management, clinical research, pharmacovigilance and data monitoring among others. It offers services across all phases of …
  • City Utilities of Springfield:発電所・企業SWOT分析
    City Utilities of Springfield - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • AngloGold Ashanti Limited:戦略・SWOT・企業財務分析
    AngloGold Ashanti Limited - Strategy, SWOT and Corporate Finance Report Summary AngloGold Ashanti Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • ReWalk Robotics Ltd (RWLK):企業の財務・戦略的SWOT分析
    Summary ReWalk Robotics Ltd (ReWalk) is a medical device company that designs, develops and commercializes exoskeletons. The company offers walk restoration devices for people with lower limb disabilities to stand and walk once again. Its products include ReWalk personal system and ReWalk rehabilita …
  • Safe Orthopaedics SA (SAFOR):企業の製品パイプライン分析2018
    Summary Safe Orthopaedics SA (Safe Orthopaedics) is medical device company that manufactures and markets devices for spinal surgery. The company’s products comprise implants and surgical instruments. It offers modular cervical cages, percutaneous auto-correction screws, modular anchorage screws, per …
  • Womble Bond Dickinson (UK) LLP:企業の戦略的SWOT分析
    Womble Bond Dickinson (UK) LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • International Seaways Inc (INSW):石油・ガス:M&Aディール及び事業提携情報
    Summary International Seaways Inc (INSW) owns and operates a fleet of oceangoing vessels involved in the transportation of crude oil and petroleum products. The company holds ownership in LNG (liquefied natural gas) carriers and FSO (floating storage and offloading) service vessels. It charters the …
  • UCB SA (UCB):企業の財務・戦略的SWOT分析
    UCB SA (UCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Forward Industries, Inc. (FORD):企業の財務・戦略的SWOT分析
    Forward Industries, Inc. (FORD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Bawag Psk
    Bawag Psk - Strategy, SWOT and Corporate Finance Report Summary Bawag Psk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • The Bank of Okinawa, Ltd. (8397):企業の財務・戦略的SWOT分析
    The Bank of Okinawa, Ltd. (8397) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • PNE Wind AG (PNE3):企業の財務・戦略的SWOT分析
    PNE Wind AG (PNE3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆